AIDS-(HIV-1)

AIDS (acquired immunodeficiency syndrome) is a stage of HIV infection in which an infected person's immune system has grown so weak that he or she is in danger of getting (or has already developed) additional infections or malignancies that might potentially lead to death.

Though all persons with AIDS are infected with HIV-1, not all people with HIV-1 infection have AIDS, and not all people with HIV-1 infection will acquire AIDS.

HIV Pathogenesis

Human immunodeficiency virus-1 (HIV-1), a member of the retrovirus family, is the cause of AIDS. Retroviruses are ribonucleic acid (RNA) viruses with an enzyme (reverse transcriptase) that converts viral RNA to deoxyribonucleic acid (DNA).

In the case of HIV-1, this DNA (now known as a DNA provirus) is then integrated into the DNA of the infected individual. When the DNA of the infected individual is transcribed, or read, by the cell's molecular machinery, the proviral DNA is also read, resulting in the generation of a new virus and its discharge from the infected cell.

HIV-1 infection pathogenesis is complicated. HIV-1 interacts with cells with certain types of molecular receptors, such as CD4 and chemokine receptors. CD4 lymphocytes, macrophages, and microglial cells in the brain all carry these receptors.

CD4 cells are a kind of T-cell helper. Macrophages are immune cells that eat infected cells, while microglial cells are immune cells that fulfill various activities in the brain.

The virus will multiply after binding and entering the cell, as previously explained. In an infected person, up to 10 billion viruses and particles can be created in a single day.

One of HIV-1's primary targets is CD4 cells. These cells are critical to the immune system's operation. Direct viral death, other lymphocytes that destroy HIV-infected cells, and maybe additional processes all contribute to the destruction of CD4 lymphocytes.

When CD4 cells are reduced, the immune system's capacity to combat infections and some malignancies is compromised. These infections and malignancies can emerge when the loss is severe enough, and they can kill the HIV-infected individual.

Medical specialists believe that the infected person has full-blown AIDS at this level of reduced CD4 cells.

Transmission

The epidemiology of HIV infection and AIDS has evolved over time.

Males who had sex with men were by far the most impacted risk group when the illness was first diagnosed in the early 1980s, followed by intravenous drug users who shared needles, those who got HIV-contaminated blood, and hemophiliacs who received infected clotting factors.

Women who had sexual contact with HIV-positive males were identified as being at high risk of getting the virus and, if pregnant, passing it on to their unborn children.

Though this disease was originally identified in the United States, instances quickly spread to other parts of the world. Sub-Saharan Africa, the Caribbean, and Asia were particularly heavily struck. At the turn of the century, it is believed that more than forty million individuals worldwide are infected, with as many as one million in the United States alone.

HIV-1 is transmitted by contaminated body fluids. By far the most prevalent mechanism of HIV transmission is sexual interaction. Anal intercourse is the most effective sexual method of spreading the virus.

The second biggest risk is vaginal intercourse, which is more dangerous for women than for men. In other words, an infected man infecting a woman through penile-vaginal intercourse is simpler than the other way around, especially if the guy is circumcised and has no sores or ulcers on his penis.

Because HIV is a blood-borne illness, those who use intravenous drugs and share needles can readily spread the virus in this way. There was a danger of contracting HIV by transfusion of blood or a blood product before testing for the virus in the blood supply, but this risk is now extremely low.

Vertical transmission, or transfer from mother to child during pregnancy, happens in approximately one-third of HIV-infected pregnant women who are not on anti-HIV drugs.

Prevention

HIV transmission prevention is both a behavioral and a medical issue.

The only definite way to avoid HIV transmission is to abstain from sexual activity. Though this is correct, premarital and extramarital sexual conduct is widespread in most civilizations.

Condoms act as an efficient barrier against sexual transmission. Social, religious, political, and cultural factors, on the other hand, intrude into condom education for teenagers and contribute to debates over sexual behavior education in general. With one-third or more of HIV infections happening in youth, vigorous and truthful teaching efforts are required. Only by understanding the implications and knowing how to avoid transmission can one make an educated decision regarding one's actions.

Aside from all of this, there are medical aspects to transmission prevention.

As previously stated, HIV-infected pregnant women who are treated with anti-HIV drugs can lower their chance of passing the infection to their unborn child.

Using anti-HIV drugs, healthcare workers who are poked with needles tainted with blood from HIV-positive patients can lower their risk of infection.

In the early twenty-first century, medical research looked at the idea of lowering the risk of HIV transmission following a sexual interaction by treating the uninfected contact with anti-HIV drugs. Vaccines against HIV are being developed in various countries of the world, but have yet to be proven to be effective.

Treatment

HIV/AIDS treatment is both hard and costly. The existing drugs suppress the reverse transcriptase enzyme as well as an enzyme that helps the virus grow into one that can infect additional cells.

A combination of at least three distinct drugs acting at these multiple locations can entirely rid the bloodstream of a virus. After treatment, the patient's immune system usually improves and, in some situations, returns to normal.

If the patient takes the medications as prescribed and the virus is suppressed, the patient may never become ill. However, the virus is still present in lymph nodes and maybe other organs.

If the patient quits taking his or her drugs or takes them inconsistently, the virus will re-enter circulation. Once the virus is created again, it is quite likely that it will evolve into a form that is resistant to the treatments that the patient was previously taking.

When this happens, especially if the patient has been on more than one pharmaceutical regimen, a virus that is resistant to all existing therapies might be chosen.

There isn't much more that can be done at this time. One big issue concerning these people is that if they continue to be sexually active or use needles, they will spread resistant viruses. This is becoming increasingly widely reported.

New drugs are being researched to see whether they may solve the resistance problem by addressing new locations of viral production or those that are unaffected by changes in the resistant virus.

The difficulties here include the chance that the patient may die before the new drugs are ready; that if the patient survives, he or she will be unable to bear the new medicines' adverse effects; and, lastly, that the patient will be unable to pay for the medicines.

In the United States, anti-HIV or anti-retroviral drugs cost more than $10,000 a year. This, along with the price of blood testing and medical visits, puts therapy out of reach for the vast majority of infected individuals worldwide.

HIV/AIDS is and will remain one of the most difficult medical difficulties that medical practitioners have ever confronted. Public health experts presently have only prevention and education to use to stop the tide of an ever-growing disease.